REGN Q4 2019 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.9B-3.3% YoY

Gross Profit

$1.6B85.2% margin

Operating Income

$676M36.3% margin

Net Income

$792M42.5% margin

EPS (Diluted)

$6.93

QoQ Revenue Growth

+6.9%

Cash Flow

Operating Cash Flow

$787M

Free Cash Flow

$648M

Stock-Based Comp.

$134M

Balance Sheet

Total Assets

$14.8B

Total Liabilities

$3.7B

Stockholders' Equity

$11.1B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.9B	$1.9B	-3.3%
Gross Profit	$1.6B	$1.8B	-10.2%
Operating Income	$676M	$718M	-5.9%
Net Income	$792M	$820M	-3.5%

Revenue Segments

Product

$1.3B100%